Stock Events

Stock Events

Synlogic 

$0.6
16
-$0-0.02% Thursday 12:00

Statistics

Day High
0.6
Day Low
0.6
52W High
1.96
52W Low
0.54
Volume
359
Avg. Volume
85,724
Mkt Cap
6.96M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.18
-0.08
0.02
0.12
Expected EPS
N/A
Actual EPS
N/A

Financials

-291,987.5%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
16,000Revenue
-46.72MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SYBX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, competing in the genetic medicine space similar to Synlogic's approach to synthetic biotics.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the field of genetic and cellular therapies where Synlogic operates.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine works on gene editing using CRISPR technology, directly competing with Synlogic in the development of novel genetic treatments.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing space, making it a competitor in the genetic therapy market.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics focuses on precision genetic medicines using base editing, a next-generation CRISPR technology, competing in the same innovative healthcare sector.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, gene editing, and gene regulation, positioning it as a competitor in the genetic treatment market.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO is a leader in the development of AAV-based gene therapies, which places it in competition with companies developing other advanced genetic therapies.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is focused on the development of programmed cellular immunotherapies for cancer and immune disorders, competing in the cell therapy space alongside Synlogic's synthetic biotics approach.

About

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Ms. Mary Beth Dooley
Employees
1
Country
US
ISIN
US87166L2097

Listings

LSE
GB
0A8U.LSE
OTC Link
US
SYBX

0 Comments

Share your thoughts

FAQ

What is Synlogic stock price today?▼
The current price of SYBX is $0.6 USD — it has decreased by -0.02% in the past 24 hours. Watch Synlogic stock price performance more closely on the chart.
What is Synlogic stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Synlogic stocks are traded under the ticker SYBX.
Is Synlogic stock price growing?▼
SYBX stock has fallen by -2.78% compared to the previous week, the month change is a -0.83% fall, over the last year Synlogic has showed a -44.91% decrease.
What is Synlogic market cap?▼
Today Synlogic has the market capitalization of 6.96M
When is the next Synlogic earnings date?▼
Synlogic is going to release the next earnings report on May 12, 2026.
What were Synlogic earnings last quarter?▼
SYBX earnings for the last quarter are 0.12 USD per share, whereas the estimation was -0.04 USD resulting in a +400% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Synlogic revenue for the last year?▼
Synlogic revenue for the last year amounts to 16,000 USD.
What is Synlogic net income for the last year?▼
SYBX net income for the last year is -46.72M USD.
How many employees does Synlogic have?▼
As of April 05, 2026, the company has 1 employees.
In which sector is Synlogic located?▼
Synlogic operates in the Health Care sector.
When did Synlogic complete a stock split?▼
The last stock split for Synlogic was on September 28, 2023 with a ratio of 1:15.
Where is Synlogic headquartered?▼
Synlogic is headquartered in Winchester, US.